Yong Sang Song

List of Publications by Year
in descending order

115 papers	3,878 citations	87888 38 h-index	149698 56 g-index
116 all docs	116 docs citations	116 times ranked	5984 citing authors

#	Article	IF	Citations
1	Ascites modulates cancer cell behavior, contributing to tumor heterogeneity in ovarian cancer. Cancer Science, 2016, 107, 1173-1178.	3.9	125
2	Unfolded protein response to autophagy as a promising druggable target for anticancer therapy. Annals of the New York Academy of Sciences, 2012, 1271, 20-32.	3.8	119
3	Mitochondrial fission causes cisplatin resistance under hypoxic conditions via ROS in ovarian cancer cells. Oncogene, 2019, 38, 7089-7105.	5.9	116
4	Curcumin induces apoptosis by inhibiting sarco/endoplasmic reticulum Ca2+ ATPase activity in ovarian cancer cells. Cancer Letters, 2016, 371, 30-37.	7.2	107
5	Tumor evolution and chemoresistance in ovarian cancer. Npj Precision Oncology, 2018, 2, 20.	5.4	106
6	Polymorphism in folate- and methionine-metabolizing enzyme and aberrant CpG island hypermethylation in uterine cervical cancer. Gynecologic Oncology, 2005, 96, 173-180.	1.4	99
7	Genetic polymorphisms affecting clinical outcomes in epithelial ovarian cancer patients treated with taxanes and platinum compounds: A Korean population-based study. Gynecologic Oncology, 2009, 113, 264-269.	1.4	92
8	Comparison of DNA hypermethylation patterns in different types of uterine cancer: Cervical squamous cell carcinoma, cervical adenocarcinoma and endometrial adenocarcinoma. International Journal of Cancer, 2006, 118, 2168-2171.	5.1	90
9	Curcumin induces ER stress-mediated apoptosis through selective generation of reactive oxygen species in cervical cancer cells. Molecular Carcinogenesis, 2016, 55, 918-928.	2.7	88
10	Association of overexpression of hexokinase II with chemoresistance in epithelial ovarian cancer. Clinical and Experimental Medicine, 2014, 14, 345-353.	3.6	79
11	Association between excision repair cross-complementation group 1 polymorphism and clinical outcome of platinum-based chemotherapy in patients with epithelial ovarian cancer. Experimental and Molecular Medicine, 2006, 38, 320-324.	7.7	78
12	Interleukin-10 promoter polymorphisms and cervical cancer risk in Korean women. Cancer Letters, 2002, 184, 57-63.	7.2	75
13	Multiple HPV infection in cervical cancer screened by HPVDNAChipâ„¢. Cancer Letters, 2003, 198, 187-192.	7.2	70
14	Resveratrol triggers ER stress-mediated apoptosis by disrupting N-linked glycosylation of proteins in ovarian cancer cells. Cancer Letters, 2016, 371, 347-353.	7.2	70
15	Ovarian cancer cell-derived lysophosphatidic acid induces glycolytic shift and cancer-associated fibroblast-phenotype in normal and peritumoral fibroblasts. Cancer Letters, 2019, 442, 464-474.	7.2	70
16	Resveratrol as a Tumor-Suppressive Nutraceutical Modulating Tumor Microenvironment and Malignant Behaviors of Cancer. International Journal of Molecular Sciences, 2019, 20, 925.	4.1	68
17	Cancerâ€specific interruption of glucose metabolism by resveratrol is mediated through inhibition of Akt/GLUT1 axis in ovarian cancer cells. Molecular Carcinogenesis, 2015, 54, 1529-1540.	2.7	67
18	Proâ€inflammatory M1 macrophage enhances metastatic potential of ovarian cancer cells through NFâ€Î°B activation. Molecular Carcinogenesis, 2018, 57, 235-242.	2.7	67

#	ARTICLE	IF	CITATIONS
19	Mitochondrial dynamics altered by oxidative stress in cancer. Free Radical Research, 2016, 50, 1065-1070.	3.3	62
20	LPA Induces Metabolic Reprogramming in Ovarian Cancer via a Pseudohypoxic Response. Cancer Research, 2018, 78, 1923-1934.	0.9	61
21	p53 and p21 genetic polymorphisms and susceptibility to endometrial cancer1. Gynecologic Oncology, 2004, 93, 499-505.	1.4	60
22	ROS accumulation by PEITC selectively kills ovarian cancer cells via UPR-mediated apoptosis. Frontiers in Oncology, 2015, 5, 167.	2.8	60
23	Expression of cyclooxygenase-2 in association with clinicopathological prognostic factors and molecular markers in epithelial ovarian cancer. Gynecologic Oncology, 2004, 92, 927-935.	1.4	58
24	PGC1Î± induced by reactive oxygen species contributes to chemoresistance of ovarian cancer cells. Oncotarget, 2017, 8, 60299-60311.	1.8	54
25	Systemic Inflammatory Response Markers and CA-125 Levels in Ovarian Clear Cell Carcinoma: A Two Center Cohort Study. Cancer Research and Treatment, 2016, 48, 250-258.	3.0	52
26	Metformin induces degradation of cyclin D1 via AMPK/GSK3Î² axis in ovarian cancer. Molecular Carcinogenesis, 2017, 56, 349-358.	2.7	51
27	Modulation of inflammatory signaling pathways by phytochemicals in ovarian cancer. Genes and Nutrition, 2011, 6, 109-115.	2.5	50
28	Metabolic orchestration between cancer cells and tumor microenvironment as a co-evolutionary source of chemoresistance in ovarian cancer: A therapeutic implication. Biochemical Pharmacology, 2014, 92, 43-54.	4.4	50
29	Hormone Interactions to Leu-rich Repeats in the Gonadotropin Receptors. Journal of Biological Chemistry, 2001, 276, 3426-3435.	3.4	49
30	Human Papillomavirus Infection and Cervical Cancer Prevention in Japan and Korea. Vaccine, 2008, 26, M30-M42.	3.8	48
31	The Role of the Hinge Region of the Luteinizing Hormone Receptor in Hormone Interaction and Signal Generation. Journal of Biological Chemistry, 2001, 276, 3451-3458.	3.4	47
32	Metabolic approaches to overcoming chemoresistance in ovarian cancer. Annals of the New York Academy of Sciences, 2011, 1229, 53-60.	3.8	46
33	Prognostic value of preoperative intratumoral FDG uptake heterogeneity in patients with epithelial ovarian cancer. European Radiology, 2017, 27, 16-23.	4.5	44
34	Lysophosphatidic acid stimulates epithelial to mesenchymal transition marker Slug/Snail2 in ovarian cancer cells via GÎ±i2, Src, and HIF1Î± signaling nexus. Oncotarget, 2016, 7, 37664-37679.	1.8	44
35	Evaluation of preoperative criteria used to predict lymph node metastasis in endometrial cancer. Acta Obstetricia Et Gynecologica Scandinavica, 2010, 89, 168-174.	2.8	43
36	Matched-case comparison for the efficacy of neoadjuvant chemotherapy before surgery in FIGO stage IB1-IIA cervical cancer. Gynecologic Oncology, 2010, 119, 217-224.	1.4	41

#	Article	IF	Citations
37	Non-coding RNAs shuttled via exosomes reshape the hypoxic tumor microenvironment. Journal of Hematology and Oncology, 2020, 13, 67.	17.0	41
38	Polymorphism of TP53 codon 72 and the risk of cervical cancer among Korean women. American Journal of Obstetrics and Gynecology, 2001, 184, 55-58.	1.3	40
39	Autophagy and protein kinase RNA-like endoplasmic reticulum kinase (PERK)/eukaryotic initiation factor 2 alpha kinase (eIF2α) pathway protect ovarian cancer cells from metformin-induced apoptosis. Molecular Carcinogenesis, 2016, 55, 346-356.	2.7	40
40	Adipose Stromal Cells from Visceral and Subcutaneous Fat Facilitate Migration of Ovarian Cancer Cells via IL-6/JAK2/STAT3 Pathway. Cancer Research and Treatment, 2017, 49, 338-349.	3.0	40
41	Hormone Interactions to Leu-rich Repeats in the Gonadotropin Receptors. Journal of Biological Chemistry, 2001, 276, 3436-3442.	3.4	39
42	A feeder-free, defined three-dimensional polyethylene glycol-based extracellular matrix niche for culture of human embryonic stem cells. Biomaterials, 2013, 34, 3571-3580.	11.4	38
43	Conventional versus nerve-sparing radical surgery for cervical cancer: a meta-analysis. Journal of Gynecologic Oncology, 2015, 26, 100.	2.2	38
44	Activation of LXRα/β by cholesterol in malignant ascites promotes chemoresistance in ovarian cancer. BMC Cancer, 2018, 18, 1232.	2.6	38
45	Prognostic value of preoperative metabolic tumor volume measured by 18F-FDG PET/CT and MRI in patients with endometrial cancer. Gynecologic Oncology, 2013, 130, 446-451.	1.4	37
46	Metformin against Cancer Stem Cells through the Modulation of Energy Metabolism: Special Considerations on Ovarian Cancer. BioMed Research International, 2014, 2014, 1-11.	1.9	37
47	Malignant ascites enhances migratory and invasive properties of ovarian cancer cells with membrane bound IL-6R *in vitro*. Oncotarget, 2016, 7, 83148-83159.	1.8	37
48	Pre-operative systemic inflammatory response markers in predicting lymph node metastasis in endometrioid endometrial adenocarcinoma. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2012, 162, 206-210.	1.1	34
49	Impact of Chemoradiation on Prognosis in Stage IVB Cervical Cancer with Distant Lymphatic Metastasis. Cancer Research and Treatment, 2013, 45, 193-201.	3.0	32
50	Interleukin-1 Beta -511 Polymorphism and Risk of Cervical Cancer. Journal of Korean Medical Science, 2007, 22, 110.	2.5	31
51	Cyclooxygenase-1 and -2: Molecular Targets for Cervical Neoplasia. Journal of Cancer Prevention, 2013, 18, 123-134.	2.0	31
52	Gene expression profiles of human subcutaneous and visceral adipose–derived stem cells. Cell Biochemistry and Function, 2016, 34, 563-571.	2.9	29
53	Paradoxical expression of *AHCYL1* affecting ovarian carcinogenesis between chickens and women. Experimental Biology and Medicine, 2012, 237, 758-767.	2.4	28
54	Impact of CT-Determined Sarcopenia and Body Composition on Survival Outcome in Patients with Advanced-Stage High-Grade Serous Ovarian Carcinoma. Cancers, 2020, 12, 559.	3.7	28

#	Article	IF	Citations
55	Plasma Gelsolin Inhibits CD8+ T-cell Function and Regulates Glutathione Production to Confer Chemoresistance in Ovarian Cancer. Cancer Research, 2020, 80, 3959-3971.	0.9	28
56	Chemopreventive and Anticancer Effects of Thymoquinone: Cellular and Molecular Targets. Journal of Cancer Prevention, 2020, 25, 136-151.	2.0	27
57	Integrated analysis of ascites and plasma extracellular vesicles identifies a miRNA-based diagnostic signature in ovarian cancer. Cancer Letters, 2022, 542, 215735.	7.2	27
58	Risk Factors Associated with Uterine Cervical Cancer in Korea: A Case-Control Study with Special Reference to Sexual Behavior. Journal of Epidemiology, 1997, 7, 117-123.	2.4	26
59	Significance of numbers of metastatic and removed lymph nodes in FIGO stage IB1 to IIA cervical cancer: Primary surgical treatment versus neoadjuvant chemotherapy before surgery. Gynecologic Oncology, 2011, 121, 551-557.	1.4	24
60	Tumour microenvironment on mitochondrial dynamics and chemoresistance in cancer. Free Radical Research, 2018, 52, 1271-1287.	3.3	24
61	Body mass index and survival in patients with epithelial ovarian cancer. Journal of Obstetrics and Gynaecology Research, 2012, 38, 70-76.	1.3	23
62	Preoperative PET/CT FDG standardized uptake value of pelvic lymph nodes as a significant prognostic factor in patients with uterine cervical cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 674-681.	6.4	23
63	Prognostic factors in neuroendocrine cervical carcinoma. Obstetrics and Gynecology Science, 2016, 59, 116.	1.6	22
64	Success Factors of Laparoscopic Nerve-sparing Radical Hysterectomy for Preserving Bladder Function in Patients with Cervical Cancer: A Protocol-Based Prospective Cohort Study. Annals of Surgical Oncology, 2015, 22, 1987-1995.	1.5	21
65	Phytochemicals in Cancer Immune Checkpoint Inhibitor Therapy. Biomolecules, 2021, 11, 1107.	4.0	21
66	Phase II evaluation of CKD-602, a camptothecin analog, administered on a 5-day schedule to patients with platinum-sensitive or -resistant ovarian cancer. Gynecologic Oncology, 2008, 109, 359-363.	1.4	19
67	Culture of preantral follicles in poly(ethylene) glycolâ€based, threeâ€dimensional hydrogel: a relationship between swelling ratio and follicular developments. Journal of Tissue Engineering and Regenerative Medicine, 2015, 9, 319-323.	2.7	19
68	Hormone Interactions to Leu-rich Repeats in the Gonadotropin Receptors. Journal of Biological Chemistry, 2001, 276, 3443-3450.	3.4	18
69	Epigenetic Therapies as a Promising Strategy for Overcoming Chemoresistance in Epithelial Ovarian Cancer. Journal of Cancer Prevention, 2013, 18, 227-234.	2.0	18
70	Safe Criteria for Less Radical Trachelectomy in Patients with Early-Stage Cervical Cancer: A Multicenter Clinicopathologic Study. Annals of Surgical Oncology, 2012, 19, 1973-1979.	1.5	17
71	Evaluating Tumor Evolution via Genomic Profiling of Individual Tumor Spheroids in a Malignant Ascites. Scientific Reports, 2018, 8, 12724.	3.3	17
72	Development of Web-Based Nomograms to Predict Treatment Response and Prognosis of Epithelial Ovarian Cancer. Cancer Research and Treatment, 2019, 51, 1144-1155.	3.0	17

#	ARTICLE	IF	CITATIONS
73	Elevation of cyclooxygenase-2 is related to lymph node metastasis in adenocarcinoma of uterine cervix. Cancer Letters, 2006, 237, 305-311.	7.2	16
74	Promoter polymorphism in the matrix metalloproteinase-1 and risk of cervical cancer in Korean women. Cancer Letters, 2005, 217, 191-196.	7.2	15
75	The C19007T Polymorphism of <i>ERCC1</i> and Its Correlation with the Risk of Epithelial Ovarian and Endometrial Cancer in Korean Women. Gynecologic and Obstetric Investigation, 2007, 64, 84-88.	1.6	15
76	Bevacizumab Efficacy and Recurrence Pattern of Persistent and Metastatic Cervical Cancer. In Vivo, 2019, 33, 863-868.	1.3	15
77	Association of ALDH1A1-NEK-2 axis in cisplatin resistance in ovarian cancer cells. Heliyon, 2020, 6, e05442.	3.2	15
78	Sulforaphene Suppresses Adipocyte Differentiation via Induction of Post-Translational Degradation of CCAAT/Enhancer Binding Protein Beta (C/EBPÎ²). Nutrients, 2020, 12, 758.	4.1	15
79	Destablilization of TRAF6 by DRAK1 Suppresses Tumor Growth and Metastasis in Cervical Cancer Cells. Cancer Research, 2020, 80, 2537-2549.	0.9	15
80	Computational modeling of malignant ascites reveals CCL5â€"SDC4 interaction in the immune microenvironment of ovarian cancer. Molecular Carcinogenesis, 2021, 60, 297-312.	2.7	15
81	ROS-Induced SIRT2 Upregulation Contributes to Cisplatin Sensitity in Ovarian Cancer. Antioxidants, 2020, 9, 1137.	5.1	14
82	Genotypic prevalence of human papillomavirus infection during normal pregnancy: A crossâ€sectional study. Journal of Obstetrics and Gynaecology Research, 2014, 40, 200-207.	1.3	13
83	Preoperative PET/CT standardized FDG uptake values of pelvic lymph nodes as a significant prognostic factor in patients with endometrial cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 1793-1799.	6.4	13
84	Aberrant expression of JNK-associated leucine-zipper protein, JLP, promotes accelerated growth of ovarian cancer. Oncotarget, 2016, 7, 72845-72859.	1.8	13
85	Prediction of Recurrence by Preoperative Intratumoral FDG Uptake Heterogeneity in Endometrioid Endometrial Cancer. Translational Oncology, 2017, 10, 178-183.	3.7	13
86	Differential effects of thymoquinone on lysophosphatidic acid-induced oncogenic pathways in ovarian cancer cells. Journal of Traditional and Complementary Medicine, 2020, 10, 207-216.	2.7	13
87	Feasibility of Radical Surgery in the Management of Elderly Patients with Uterine Cervical Cancer in Korea. Gynecologic and Obstetric Investigation, 2005, 59, 165-170.	1.6	12
88	Comparison of the efficacy between topotecanâ€•and belotecanâ€, a new camptothecin analog, based chemotherapies for recurrent epithelial ovarian cancer: A single institutional experience. Journal of Obstetrics and Gynaecology Research, 2010, 36, 86-93.	1.3	12
89	Decursin and Decursinol Angelate Suppress Adipogenesis through Activation of Î²-catenin Signaling Pathway in Human Visceral Adipose-Derived Stem Cells. Nutrients, 2020, 12, 13.	4.1	11
90	Phase I/IIa Study of Combination Chemotherapy with CKDâ€602 and Cisplatin in Patients with Recurrent Epithelial Ovarian Cancer. Annals of the New York Academy of Sciences, 2009, 1171, 627-634.	3.8	10

#	ARTICLE	IF	CITATIONS
91	Prognostic implications of body composition change during primary treatment in patients with ovarian cancer: A retrospective study using an artificial intelligence-based volumetric technique. Gynecologic Oncology, 2021, 162, 72-79.	1.4	10
92	Prognostic implication of the metastatic lesion-to-ovarian cancer standardised uptake value ratio in advanced serous epithelial ovarian cancer. European Radiology, 2017, 27, 4510-4515.	4.5	8
93	GNAi2/gip2-Regulated Transcriptome and Its Therapeutic Significance in Ovarian Cancer. Biomolecules, 2021, 11, 1211.	4.0	8
94	Degradation of DRAK1 by CUL3/SPOP E3 Ubiquitin ligase promotes tumor growth of paclitaxel-resistant cervical cancer cells. Cell Death and Disease, 2022, 13, 169.	6.3	8
95	Piceatannol Is Superior to Resveratrol at Suppressing Adipogenesis in Human Visceral Adipose-Derived Stem Cells. Plants, 2021, 10, 366.	3.5	7
96	Unraveling Autocrine Signaling Pathways through Metabolic Fingerprinting in Serous Ovarian Cancer Cells. Biomedicines, 2021, 9, 1927.	3.2	7
97	A multicentre, randomised, open-label, parallel-group Phase 2b study of belotecan versus topotecan for recurrent ovarian cancer. British Journal of Cancer, 2021, 124, 375-382.	6.4	6
98	Increasing trend in the incidence of cervical cancer among the elderly in Korea: A population-based study from 1993 to 2002. Acta Oncológica, 2007, 46, 852-858.	1.8	5
99	Favorable factors for preserving bladder function after nerve‐sparing radical hysterectomy: A protocol‐based validation study. Journal of Surgical Oncology, 2017, 116, 492-499.	1.7	5
100	Prognostic importance of peritoneal lesion-to-primary tumour standardized uptake value ratio in advanced serous epithelial ovarian cancer. European Radiology, 2018, 28, 2107-2114.	4.5	5
101	Sarcopenia: Clinical implications in ovarian cancer, diagnosis, etiology, and management. Sports Medicine and Health Science, 2020, 2, 202-210.	2.0	5
102	Nuclear HKII‐P-p53 (Ser15) Interaction is a Prognostic Biomarker for Chemoresponsiveness and Glycolytic Regulation in Epithelial Ovarian Cancer. Cancers, 2021, 13, 3399.	3.7	5
103	Matched-Case Comparison for the Role of Surgery in FIGO Stage Ib1‐IIa Squamous Cell Carcinoma of Cervix and Suspicious Para-Aortic Lymph Node Metastasis. Annals of Surgical Oncology, 2009, 16, 133-9.	1.5	4
104	Wnt/β-Catenin Inhibition by CWP232291 as a Novel Therapeutic Strategy in Ovarian Cancer. Frontiers in Oncology, 2022, 12, .	2.8	4
105	Stress Response, Inflammaging, and Cancer. , 2014, , 49-53.		3
106	Molecular and Cellular Basis of Chemoresistance in Ovarian Cancer. , 2019, , 575-593.		2
107	Laterally Extended Endopelvic Resection Versus Chemo or Targeted Therapy Alone for Pelvic Sidewall Recurrence of Cervical Cancer. Frontiers in Oncology, 2021, 11, 683441.	2.8	2
108	Cyclooxygenase expressions and response to radiation therapy in uterine cervix cancer. Korean Journal of Gynecologic Oncology, 2006, 17, 105.	0.1	1

#	Article	IF	Citations
109	Identification of Patients with Recurrent Epithelial Ovarian Cancer Who Will Benefit from More Than Three Lines of Chemotherapy. Cancer Research and Treatment, 2022, 54, 1219-1229.	3.0	1
110	Targeting cancer stem cells with phytoceuticals for cancer therapy. , 2020, , 329-357.		0
111	Eight Cases of Synchronous Primary Carcinomas of The Endometrium and The Ovary. Korean Journal of Gynecologic Oncology and Colposcopy, 2001, 12, 203.	0.0	0
112	Treatment Efficacy of High-Dose Megestrol Acetate (Megace) in Young Women with Early Stage of Endometrial Carcinoma. Korean Journal of Gynecologic Oncology and Colposcopy, 1998, 9, 300.	0.0	0
113	Cycloxygenase. , 2016, , 1-8.		0
114	The second annual conference of International ovarian cancer consortium and the symposium on tumor microenvironment and therapeutic resistance. Genes and Cancer, 2016, 7, 7-12.	1.9	0
115	Cycloxygenase. , 2018, , 1275-1282.		0